Development and Validation of Novel UPLC-MS/MS Method for the Analysis of Macitentan in Pharmaceutical Formulations
CURRENT PHARMACEUTICAL ANALYSIS, cilt.15, sa.5, ss.554-559, 2019 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 15 Sayı: 5
- Basım Tarihi: 2019
- Doi Numarası: 10.2174/1573412915666190314142531
- Dergi Adı: CURRENT PHARMACEUTICAL ANALYSIS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.554-559
- Anahtar Kelimeler: Macitentan, pulmonary arterial hypertension, UPLC-MS/MS, validation, pharmaceutical formulations, specificity, ENDOTHELIN RECEPTOR ANTAGONIST, PHARMACOKINETICS
- Atatürk Üniversitesi Adresli: Evet
Özet
Introduction: Macitentan is an endothelin receptor antagonist drug used in the treatment of pulmonary arterial hypertension.